3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
The Lancet Psychiatry May 1, 2018 Michael C Mithoefer, Ann T Mithoefer, Allison A. Feduccia et al. 443 citations
Background: Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population. Methods: We did a randomised, double-blind, dose-response,...
DOI: 10.1016/s2215-0366(18)30135-4 (opens in new tab)
This condition
PTSD Symptoms
Profound trauma
Significant relief
+10